

Anti-Nectin-4 (Enfortumab), Human IgG1 Antibody

rev 10/20

CATALOG NO.: A2176-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant antibody to Enfortumab without the drug conjugation. The original antibody-drug conjugate (Enfortumab Vedotin) comprises an anti-Nectin-4 human monoclonal antibody that is chemically linked to a microtubule disrupting drug, monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, arrests cell cycle, and induces apoptosis. The original ADC is approved by the FDA to treat metastatic bladder cancer patients, who were previously treated with platinum-containing chemotherapy, or PD-1/PD-L1 checkpoint inhibitors.

ALTERNATE NAMES: AGS-22CE, AGS-22M, AGS-22M6E, unconjugated:AGS-22C3, AGSM6, LNIR, PRR4, EDSS1, PVRL4

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human Nectin-4

CAS NUMBER: 1346452-25-2

MOLECULAR WEIGHT: 152 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-L1 Humanized Antibody (A1305)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
 Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)

FOR RESEARCH USE ONLY! Not to be used on humans.